ZIOPHARM: Key Oncology Catalyst Approaching
Long Ideas - The war against cancer has proven to be a difficult war to win. For decades, researchers and doctors have looked for ways to more effectively … Continue Reading
Read NowResearch
Alexion Pharmaceuticals: On the Road from Orphan Drugs to Blockbuster Profits
Long Ideas - Many biotechnology companies choose to focus on specific niches of the market that they deem to be the most lucrative. Gilead Sciences (NASDAQ:GILD) is making … Continue Reading
Read NowSCLN On Solid Ground; Stock Cheap, And Large Investors Are Buying
Long Ideas - Some notable investors have significantly increased their positions in SciClone Pharmaceuticals (NASDAQ:SCLN) recently, and the stock is expected to work higher on this news plus … Continue Reading
Read NowVIVUS: Does the Company Have a Place in the Obesity Market?
Long Ideas - Few diseases have a more pressing need for treatment than obesity. For well over a decade, there have been no new obesity drugs on the … Continue Reading
Read NowBioLife Solutions: Accelerating Growth, and Continued Upside Potential
Long Ideas - Investors who choose to invest in speculative stocks often choose the biotechnology sector as their sector of choice. It’s easy to understand why; biotechnology companies … Continue Reading
Read NowWhat To Expect From KERX’s Upcoming Phase III Results For Zerenex; Low Risk/High Reward Prospects
Long Ideas - In the next several weeks, Keryx Biopharmaceuticals (KERX) will release results from 4 key Phase III trials for its primary drug candidate, Zerenex. The drug … Continue Reading
Read NowCelgene: An Upside Surprise for Abraxane and a Clear Path to Continued Growth
Long Ideas - On Friday November 9th, Celgene (NASDAQ:CELG) released top-line data from its phase III 1st-line metastatic pancreatic cancer trial and noted that the study met its … Continue Reading
Read Now